

Content Indices

SASB Index	47
GRI Index	49
Company Topic-Specific Disclosures	52
Glossary	53
Legal Disclaimers	54

SASB Index

SASB Topic & Code	Accounting Metric	Report Section	Omissions
Activity Metric HC-MS-000.A	Number of units sold by product category.	ESG Performance Data	Given the breadth and diversity of Alcon's product portfolio, Alcon does not disclose this data.
Affordability & Pricing HC-MS-240a.1	Ratio of weighted average rate of net price increases (for all products) to the annual increase in the US Consumer Price Index.	ESG Performance Data	
Affordability & Pricing HC-MS-240a.2	Description of how price information for each product is disclosed to customers or to their agents.	Access, Affordability & Pricing; Disclosure of Pricing Information	Disclosure does not include whether the range, median, or typical price are provided to customers; does not include the frequency of confidentiality clauses in purchasing agreements with health care providers that restrict them from sharing with third parties the price they paid.
Product Safety HC-MS-250a.1	Number of recalls issued, total units recalled.	ESG Performance Data	
Product Safety HC-MS-250a.2	List of products listed in the FDA's MedWatch Safety Alerts for Human Medical Products database.	ESG Performance Data	
Product Safety HC-MS-250a.3	Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device Experience.	ESG Performance Data	
Product Safety HC-MS-250a.4	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices, by type.	ESG Performance Data	
Ethical Marketing HC-MS-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims.	ESG Performance Data	

SASB Topic & Code	Accounting Metric	Report Section	Omissions
Ethical Marketing HC-MS-270a.2	Description of code of ethics governing promotion of off-label use of products.	Business Ethics - Preventing Off-Label Use	
Product Design & Lifecycle Management HC-MS-410a.1	Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products and meet demand for sustainable products.	Sustainable Products & Services - Compliance With Chemical Regulations	
Product Design & Lifecycle Management HC-MS-410a.2	Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipment and (2) supplies.	Sustainable Products & Services - Reprocessing Used or Obsolete Equipment	Alcon replaced this metric based on the lack of available data.
Supply Chain Management HC-MS-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product quality.	ESG Performance Data	
Supply Chain Management HC-MS-430a.2	Description of efforts to maintain traceability within the distribution chain.	Responsible Procurement & Supply Chain - Track & Trace Program	
Supply Chain Management HC-MS-430a.3	Description of the management of risks associated with the use of critical materials.	Responsible Procurement & Supply Chain - Critical Materials	Disclosure does not identify the critical materials that present a significant risk to Alcon's operations, the type of risk(s) they represent.
Business Ethics HC-MS-510a.1	Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption.	ESG Performance Data	
Business Ethics HC-MS-510a.2	Description of code of ethics governing interactions with health care professionals.	Business Ethics - Code of Ethics & Healthcare Professionals	

GRI Index

General Disclosures		Report Section or Direct Response	Page
ORGANIZATIONAL PROFILE			
GRI 102: General Disclosures 2016	102-1: Name of the Organization	Alcon Inc.	
	102-2: Activities, brands, products, and services	Our Story - Company Overview	5
	102-3: Location of headquarters	Our Story - Company Overview	5
	102-4: Location of operations	Our Story - Company Overview	5
	102-5: Ownership and legal form	Alcon is a publicly traded company traded on the New York Stock Exchange and SIX Swiss Exchange.	
	102-6: Markets served	Our Story - Company Overview	5
	102-7: Scale of the organization	Our Story - Company Overview See our 2019 Annual Report for additional information on net revenues and quantity of products provided in 2019.	5
	102-8: Information on employees and other workers	As of 2019, approximately 41% of our full time associates are based in the US, followed by 10.4% in Germany and 5.1% in Indonesia.	
	102-10: Significant changes to the organization and its supply chain	As of 2019, Alcon completed its spinoff from Novartis, and it is trading as an independent company.	
STRATEGY			
GRI 102: General Disclosures 2016	102-14: Statement from senior decision-maker	A Message From Our CEO	3
ETHICS AND INTEGRITY			
GRI 102: General Disclosures 2016	102-16: Values, principles, standards and norms of behavior	Our Story - Alcon Blueprint; Business Ethics	6; 35
	102-17: Mechanisms for advice and concerns about ethics	Business Ethics - Reporting Concerns	36
GOVERNANCE			
GRI 102: General Disclosures 2016	102-18: Governance structure	The Governance and Nomination Committee oversees the Company's global strategy for corporate governance, environmental stewardship, sustainability, and corporate social responsibility. See the Governance section of our website for additional information on Alcon's governance structure.	
	102-20: Executive-level responsibility for economic, environmental, and social topics	Sustainability Governance	8
	102-23: Chair of the highest governance body	The Chair of the Alcon Board of Directors is a separately held position from the Chief Executive Officer.	

General Disclosures	Report Section or Direct Response	Page
102-24: Nominating and selecting the highest governance body	See the Governance and Nomination Committee Charter.	
102-32: Highest governance body's role in sustainability reporting	Alcon's Governance and Nomination Committee reviewed and approved this Corporate Responsibility Report.	
REPORTING PRACTICES		
GRI 102: General Disclosures 2016		
102-45: Entities included in consolidated financial statements	See our 2019 Annual Report for a list of all entities included in our consolidated financial statements.	
102-46: Defining report content and topic boundaries	About this Report - Defining Report Content	8
102-47: List of material topics	About this Report - Materiality	8
102-48: Restatements of information	As this is Alcon's first Corporate Responsibility Report, we have not made any restatements of information for 2019.	
102-49: Changes in reporting	As this is Alcon's first Corporate Responsibility Report, we have not made any significant changes in reporting for 2019.	
102-50: Reporting period	This 2019 Corporate Responsibility Report covers Alcon's operations from January 1, 2019, through December 31, 2019, unless otherwise indicated.	
102-51: Date of most recent report	This is Alcon's inaugural Corporate Responsibility Report as an independent company.	
102-52: Reporting cycle	We plan to publish a Corporate Responsibility Report annually.	
102-53: Contact point for questions regarding the report	For further questions, please email the Investor Relations team at investor.relations@alcon.com.	
102-54: Claims of reporting in accordance with the GRI Standards	We referenced the GRI Standards in the development of this Sustainability Report.	
102-55: GRI Content index	Content Indices - GRI Index	49-51
102-56: External assurance	Alcon is not conducting external assurance of our Corporate Responsibility Report at this time.	

GRI Topic-Specific Disclosures		Report Section or Direct Response	Page
ENERGY			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Reducing Our Environmental Footprint - Energy Usage	24
	103-2: The management approach and its components	Environmental Sustainability Strategy	21
	103-3: Evaluation of the management approach	Reducing Our Environmental Footprint - Energy Usage	24
GRI 302: Energy 2016	302-3: Energy intensity	ESG Performance Data - Environmental Performance	43
WATER			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Reducing Our Environmental Footprint - Water Management	24
	103-2: The management approach and its components	Environmental Sustainability Strategy	21
	103-3: Evaluation of the management approach	Reducing Our Environmental Footprint - Water Management	24
GRI 303: Water and Effluents 2018	303-5: Water consumption	ESG Performance Data - Environmental Performance	43
EMISSIONS			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Reducing Our Environmental Footprint - Greenhouse Gas Emissions	25
	103-2: The management approach and its components	Environmental Sustainability Strategy	21
	103-3: Evaluation of the management approach	Reducing our Environmental Footprint - Greenhouse Gas (GHG) Emissions	25
GRI 305: Emissions 2016	305-4: Emissions intensity	ESG Performance Data - Environmental Performance	43
EFFLUENTS AND WASTE			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Reducing Our Environmental Footprint - Waste Minimization	25
	103-2: The management approach and its components	Environmental Sustainability Strategy	21
	103-3: Evaluation of the management approach	Reducing Our Environmental Footprint - Waste Minimization	25
GRI 306: Effluents and Waste 2016	306-2: Waste by type and disposal method	ESG Performance Data - Environmental Performance	43
TALENT ATTRACTION AND RETENTION			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Talent Attraction & Retention	27
	103-2: The management approach and its components	Talent Attraction & Retention	27-28
	103-3: Evaluation of the management approach	Talent Attraction & Retention - Our Results	28
GRI 401: Employment 2016	401-1: New employee hires and employee turnover	ESG Performance Data - Talent Attraction & Retention	44
OCCUPATIONAL HEALTH AND SAFETY			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Health & Safety	31
	103-2: The management approach and its components	Health & Safety	31-33
	103-3: Evaluation of the management approach	Health & Safety - Our Results	33
GRI 403: Occupational Health and Safety 2018	403-9: Work-related injuries	ESG Performance Data - Safety Performance	44
DIVERSITY AND EQUAL OPPORTUNITY			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Diversity & Inclusion	29
	103-2: The management approach and its components	Diversity & Inclusion	29-30
	103-3: Evaluation of the management approach	Diversity & Inclusion - Our Results	30
GRI 405: Diversity and Equal Opportunity 2016	405-1: Diversity of governance bodies and employees	ESG Performance Data - Diversity & Inclusion	44

Company Topic-Specific Disclosures

Other Disclosures		Report Section or Direct Response	Page
MEDICAL INNOVATION			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Medical Innovation	10
	103-2: The management approach and its components	Medical Innovation	10-12
	103-3: Evaluation of the management approach	Medical Innovation - Our Results	10
Self-Selected Metrics	Number of first-to-market launches	Medical Innovation - Our Results; ESG Performance Data - R&D Productivity	10, 42
	Number of product approvals (major markets)	Medical Innovation - Our Results; ESG Performance Data - R&D Productivity	10, 42
PRODUCT QUALITY AND PATIENT SAFETY			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Product Quality & Patient Safety	13
	103-2: The management approach and its components	Product Quality & Patient Safety	13-14
	103-3: Evaluation of the management approach	Product Quality & Patient Safety - Our Results	14
Self-Selected Metric	HC-MS-250a.1: Number of recalls issued, total units recalled	ESG Performance Data - Quality Management System	42
	HC-MS-250a.2: Products listed in the FDA's MedWatch Safety Alerts for Human Medical Products database	ESG Performance Data - Quality Management System	42
	HC-MS-250a.3: Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device Experience	ESG Performance Data - Quality Management System	42
	HC-MS-250a.4: Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	ESG Performance Data - Quality Management System	42
ACCESS, AFFORDABILITY AND PRICING			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Access, Affordability & Pricing	15
	103-2: The management approach and its components	Access, Affordability & Pricing	15-16
	103-3: Evaluation of the management approach	Access, Affordability & Pricing - Our Results	16
Self-Selected Metrics	HC-MS-240a.1: Ratio of weighted average rate of net price increases (for all products) to the annual increase in the US Consumer Price Index	ESG Performance Data - Relative Price Performance	43
SUSTAINABLE PRODUCTS AND SERVICES			
GRI 103: Management Approach 2016	103-1: Explanation of the material topic and its boundary	Environmental Sustainability Strategy; Sustainable Products & Services	21-22
	103-2: The management approach and its components	Environmental Sustainability Strategy; Sustainable Products & Services	21-23
	103-3: Evaluation of the management approach	Environmental Sustainability Strategy; Sustainable Products & Services	21-23
Self-Selected Metric	Weight of reprocessed parts shipped (metric tons)	Sustainable Products & Services - Reprocessing Used or Obsolete Equipment	23